ReviewCancer science2018
Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment.
Review in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Advances and Hurdles of PLGA-Based Therapy for Pancreatic Cancer.AAPS PharmSciTech · 2026Review
- Microarray chip to fabricate 3D PDAC heterospheroids with architectural organization towards tumor invasion and chemoresistance study.Microsystems & nanoengineering · 2026Article
- Stromal homeostasis-restoring "rocket-like" nanomedicine inhibited pancreatic tumor growth in vivo.Materials today. Bio · 2026Article
- Developing virtual physiology of human tumor tissue for malignancy assessment.NPJ precision oncology · 2026Article
- Quantitative assessment of extravasation of IL-15-secreting MSLN-CAR-NK-92 cells using tumor transparency imaging.Theranostics · 2026Article
- Cancer-Associated Fibroblast-Targeted Nanomedicine in Solid Tumor Therapy: From Mechanisms of Therapeutic Resistance to Precision Stromal Modulation.International journal of nanomedicine · 2026Review
- Collagen Signaling via DDR1 Exacerbates Barriers to Macromolecular Drug Delivery in a 3D Model of Pancreatic Cancer Fibrosis.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- pH-Responsive Liposomes for Targeted Detection of Pancreatic Adenocarcinoma Using MSOT.Chemical & biomedical imaging · 2025Article
- Strategies for Pancreatic Cancer-Responsive Nanodrug Platforms Targeting Tumor Hypoxic Environments.International journal of nanomedicine · 2025Review
- Research advances in immune agonists and their nanoparticles for enhancing the immunotherapeutic efficacy of PD-1 inhibitors in malignancies.Frontiers in oncology · 2025Review
- Impact of stroma remodeling on forces experienced by cancer cells and stromal cells within a pancreatic tumor tissue.Biomedical engineering online · 2024Article
- Prospect of Gold Nanoparticles in Pancreatic Cancer.Pharmaceutics · 2024Review
- Modulated Electro-Hyperthermia Accelerates Tumor Delivery and Improves Anticancer Activity of Doxorubicin Encapsulated in Lyso-Thermosensitive Liposomes in 4T1-Tumor-Bearing Mice.International journal of molecular sciences · 2024Article
- Safety and Efficacy of Single-Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia.Cancers · 2024Article
- Modeling Physical Forces Experienced by Cancer and Stromal Cells Within Different Organ-Specific Tumor Tissue.IEEE journal of translational engineering in health and medicine · 2024Article
- Efficient semi-supervised semantic segmentation of electron microscopy cancer images with sparse annotations.bioRxiv : the preprint server for biology · 2023Article
- Relationships between physical and immunological tumor microenvironment in pancreatic ductal adenocarcinoma.Cancer science · 2023Article
- Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2023Review
- Drug Delivery Strategies for the Treatment of Pancreatic Cancer.Pharmaceutics · 2023Review
- Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is known for its dismal prognosis despite efforts to improve therapeutic outcome. Recently, cancer nanomedicine, application of nanotechnology to cancer diagnosis and treatment, has gained interest for treatment of pancreatic cancer. The enhanced permeability and retention (EPR) effect that promotes selective accumulation of nanometer-sized molecules within tumors is the theoretical rationale of treatment. However, it is clear that EPR may be insufficient in pancreatic cancer as a result of stromal barriers within the tumor microenvironment (TME). These limit intratumoral accumulation of macromolecules. The TME and stromal barriers inside it consist of various stromal cell types which interact both with each other and with tumor cells. We are only beginning to understand the complexities of the stromal barriers within the TME and its functional consequences for nanomedicine. Understanding the complex crosstalk between barrier stromal cells is challenging because of the difficulty of modeling pancreatic cancer TME. Here we provide an overview of stromal barriers within the TME. We also describe the preclinical models, both in vivo and in vitro, developed to study them. We furthermore discuss the critical gaps in our understanding, and how we might formulate a better strategy for using nanomedicine against pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.